Robert Habib (Credit: Imperial College London)
September 10, 2020 06:32 AM EDT
Financing
Cell/Gene Tx

Mi­NA Ther­a­peu­tics bags near­ly $30M Se­ries A to push ac­ti­vat­ing mR­NA tech through the clin­ic

Nicole DeFeudis

Editor

Sev­en years af­ter leav­ing in­vest­ment bank­ing to take the helm at Mi­NA Ther­a­peu­tics, CEO Robert Habib is on a mis­sion to de­vel­op a “new class …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times